ACKR3 and coronary artery disorder: A limitation on thrombin-induced generation of LPCs in human platelets, as offered by CXCR7-agonist VUF11207, may be considered advantageous over aspirin, which inhibits COX-1 downstream of phospholipases so that atherogenic LPCs can be generated and remain elevated in platelets from CAD patients, despite anti-platelet and statin therapy [63,76,96].